Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1,644,695
-
Total 13F shares
-
26,880,629
-
Share change
-
-5,879,991
-
Total reported value
-
$5,543,705
-
Put/Call ratio
-
0%
-
Price per share
-
$0.21
-
Number of holders
-
52
-
Value change
-
-$1,490,558
-
Number of buys
-
26
-
Number of sells
-
25
Institutional Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q4 2024
As of 31 Dec 2024,
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) was held by
52 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
26,880,629 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, BlackRock, Inc., Samsara BioCapital, LLC, VANGUARD GROUP INC, Ikarian Capital, LLC, GEODE CAPITAL MANAGEMENT, LLC, GOLDMAN SACHS GROUP INC, ADAR1 Capital Management, LLC, STATE STREET CORP, and UBS Group AG.
This page lists
51
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.